Short Interest Coverage: Will Arrowhead Pharmaceuticals Incorporated (NASDAQ:ARWR) Run Out of Steam Soon? Short Interest Is Down

November 24, 2016 - By Ruchi Gupta   ·   0 Comments

Short Interest Coverage: Will Arrowhead Pharmaceuticals Incorporated (NASDAQ:ARWR) Run Out of Steam Soon? Short Interest Is Down

The stock of Arrowhead Pharmaceuticals Incorporated (NASDAQ:ARWR) registered a decrease of 10.66% in short interest. ARWR’s total short interest was 10.21M shares in November as published by FINRA. Its down 10.66% from 11.43 million shares, reported previously. With 460,500 shares average volume, it will take short sellers 22 days to cover their ARWR’s short positions. The short interest to Arrowhead Pharmaceuticals Incorporated’s float is 17.89%. The stock increased 1.13% or $0.05 on November 23, hitting $4.49. About 1.71M shares traded hands or 62.86% up from the average. Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has declined 28.27% since April 22, 2016 and is downtrending. It has underperformed by 33.68% the S&P500.

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, is a biopharmaceutical company. The company has a market cap of $278.41 million. The Firm is engaged in developing RiboNucleic Acid interference therapeutics. It currently has negative earnings. The Company’s products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA.

Insitutional Activity: The institutional sentiment is 0 in Q2 2016. Its the same as in 2016Q1. The ratio is the same, as 67 funds sold all Arrowhead Pharmaceuticals Inc shares owned while 0 reduced positions. only 0 funds bought stakes while 0 increased positions. They now own 6,170 shares or 99.97% less from 18.16 million shares in 2016Q1.
Hanson & Doremus Investment Management last reported 470 shares in the company. Great West Life Assurance Communication Can holds 5,700 shares or 0% of its portfolio.

Insider Transactions: Since August 22, 2016, the stock had 0 insider buys, and 1 insider sale for $160,000 net activity. 20,000 shares were sold by Myszkowski Kenneth Allen, worth $160,000.

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Ratings Coverage

Out of 3 analysts covering Arrowhead Research Corp (NASDAQ:ARWR), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Arrowhead Research Corp has been the topic of 5 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Friday, August 19 by Cantor Fitzgerald. Chardan Capital Markets initiated the stock with “Buy” rating in Thursday, May 19 report. On Thursday, November 10 the stock rating was maintained by Chardan Capital Markets with “Buy”. The company was maintained on Friday, September 25 by Piper Jaffray. RBC Capital Markets maintained Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) on Wednesday, August 5 with “Hold” rating.

ARWR Company Profile

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, incorporated on February 13, 2001, is a biopharmaceutical company. The Firm is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. RNAi therapeutics leverage this natural pathway of gene silencing to target and shut down specific disease causing genes. The Company’s products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. The Company’s ARC-520 is an RNAi therapeutic designed to treat chronic hepatitis B virus (HBV) infection by reducing the expression and release of new viral particles and viral proteins with the goal of achieving a functional cure for HBV. The Firm is conducting multiple Phase IIb clinical efficacy studies. The Company’s ARC-AAT is an unlocked nucleobase analog (UNA), which contains RNAi therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD), a rare genetic disease that can damage the liver and lungs of affected individuals. The Firm is conducting a Phase Ib clinical trial for ARC-AAT. The study is a multi-center, randomized, placebo-controlled, double blind, single dose-escalation, first-in-human study to evaluate the safety, tolerability and pharmacokinetics of ARC-AAT and the effect on circulating AAT levels.

More notable recent Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) news were published by: Fool.com which released: “Why Arrowhead Pharmaceuticals Inc. Is Plummeting Today” on November 09, 2016, also Businesswire.com with their article: “Robbins Arroyo LLP: Arrowhead Pharmaceuticals, Inc. (ARWR) Misled Shareholders …” published on November 23, 2016, Fool.com published: “What’s Next for Arrowhead Pharmaceuticals, Inc. After the Stock Meltdown?” on November 10, 2016. More interesting news about Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) were released by: Prnewswire.com and their article: “ARWR LOSS ALERT: Rosen Law Firm Reminds Arrowhead Pharmaceuticals, Inc …” published on November 22, 2016 as well as Businesswire.com‘s news article titled: “Arrowhead Pharmaceuticals Announces Closing of License and Collaboration …” with publication date: November 21, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ruchi Gupta


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>